Medscape April 3, 2025
Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction.
CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy benefit managers (PBMs) that collectively control about 80% of all prescriptions in the United States, are now pivoting away from Humira and preferring biosimilars on their formularies.
But rather than preferring multiple biosimilars on their formularies, these companies have created their own subsidiaries to co-produce these medications. With this approach, known as white or private labeling, these companies can produce a medication and subsequently prefer that same drug on their formularies.
Experts are divided on whether these companies’ control of multiple stages of the drug supply chain will be beneficial or detrimental to the...
Today's Sponsors
Today's Sponsor